Soluble microneedle patch for treating human herpes virus type 8 infection by jointly delivering ganciclovir and adriamycin and preparation method of soluble microneedle patch
By preparing conical soluble microneedle patches and using HA material and PDMS molding method, the permeability and toxic side effects of ganciclovir in the treatment of human herpesvirus type 8 were solved, achieving targeted therapy and curative effect of the drug.
Patent Information
- Application Number
- CN202411338242.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-25
- Publication Date
- 2024-11-12
AI Technical Summary
Ganciclovir currently has issues with nonspecificity and low transmembrane capacity when treating human herpesvirus 8, resulting in numerous toxic side effects. Furthermore, doxorubicin only has an effect on tumors and has no antiviral effect, thus lacking a fundamental cure.
Using soluble microneedle patch technology, conical microneedles are prepared by PDMS molding method. The needle body is made of biocompatible and biodegradable HA material. Combined with doxorubicin and ganciclovir, the drug is enriched at the needle tip, improving skin penetration and drug utilization.
This approach achieves targeted therapy with ganciclovir, improves drug penetration and accumulation in the skin, reduces toxic side effects, and achieves a therapeutic effect that addresses both the symptoms and the root cause.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The invention relates to the field of biomedical materials, in particular to a soluble microneedle for delivering a combined drug of ganciclovir and doxorubicin and a preparation method thereof. Background Art
[0002] Ganciclovir (GCV) is a 2'-deoxyguanine nucleotide derivative that inhibits the replication of herpes virus and is a broad-spectrum antiviral drug. For example, CN1732942 discloses the use of ganciclovir and a recombinant adenovirus-thymidine kinase construct (ADV-TK) in the preparation of a drug for treating tumors. Ganciclovir can be administered by intravenous drip at 5 mg / kg, once every 12 hours, for 14 consecutive days. The clinical pre-test results show that the combination of ganciclovir and ADV-TK has high anti-tumor activity and significant efficacy, with an effective rate of more than 70%, fast onset of effect, and basically no toxic side effects. It is safe and convenient for clinical application.
[0003] Human Herpesivirus-8 (HHV-8) is a carcinogenic virus, also known as Kaposi's Sarcoma-associated Herpesvirus (KSHV). According to virological classification, it belongs to the γ-herpesvirus family and is a double-stranded DNA virus. Kaposi's sarcoma (KS) caused by HHV-8 is the most common tumor and cause of death in AIDS patients. Clinically, it often manifests as endothelial cell invasion such as multiple spots or plaques on the skin.
[0004] GCV triphosphate inhibits viral DNA synthesis through the following pathways: first, it competes with guanosine triphosphate to inhibit viral DNA polymerase; second, it binds to the DNA of viruses and host cells, leading to the termination of viral DNA synthesis. Compared with other drugs, GCV has become the most widely used anti-HHV-8 drug in clinical practice. In patients infected with HHV-8, GCV has been shown to effectively reduce the viral load of HHV-8 in peripheral blood and reduce viral shedding in saliva.
[0005] Although GCV can inhibit the DNA polymerase of HHV-8, GCV still faces the problems of non-specific infection site and low transmembrane ability, which leads to many toxic side effects, such as various types of thrombocytopenia, persistent bone marrow suppression, liver and kidney damage. Therefore, it is a huge clinical challenge to establish a GCV delivery system that can increase the concentration of GCV in target cells. In addition, doxorubicin (DOX) is a commonly used chemotherapy drug for HHV-8-induced tumors, but it only works on the malignant manifestations of tumors and does not play a fundamental role in antiviral treatment. Therefore, the combination of GCV and doxorubicin to establish a delivery system can simultaneously treat the symptoms and the root cause.
[0006] In recent years, microneedle drug delivery has been widely used in the biomedical field. Microneedle drug delivery can overcome the problems of low drug utilization and poor patient compliance in traditional drug delivery methods. It is flexible and spatiotemporally selective. It is a micro-invasive drug delivery method that combines the advantages of subcutaneous injection and skin patch. After the soluble microneedle pierces the stratum corneum of the epidermis of the skin, a channel is formed. As the microneedle dissolves, the drug enters the skin along the channel, which improves the drug penetration rate, uptake rate and accumulation in specific parts. Summary of the invention
[0007] The present invention provides a method for preparing a soluble microneedle patch with needle-tip enriched ganciclovir and doxorubicin hydrochloride drugs, wherein the combined drugs are enriched at the position of the microneedle tips by a two-step centrifugal drying method, the microneedle tips are conical, have sharp tips for penetrating the skin, and a certain flexible base provides mechanical support to improve the accuracy of skin penetration into irregular surfaces, further improve drug utilization, thereby enabling rapid release of drugs from the microneedles, achieving local administration, and treating human herpes virus type 8.
[0008] To achieve the above-mentioned purpose, the present invention is implemented through the following technical scheme: the soluble microneedle patch of the ganciclovir-doxorubicin combination drug comprises a needle body and a backing layer, the needle body comprises a needle body matrix material and the drugs ganciclovir and doxorubicin hydrochloride, the needle body is arranged in an array on the backing layer, and the microneedle array is arranged neatly and has a uniform morphology.
[0009] The ganciclovir-doxorubicin combined drug soluble microneedle patch is an integrated microneedle patch prepared by a PDMS mold method, and the needle body matrix material and the backing layer material are both HA, a biocompatible and degradable material.
[0010] Furthermore, the content ratio of doxorubicin hydrochloride, ganciclovir, and HA in the needle body of the combined drug soluble microneedle patch is 40 mg: 4.3 mg: 300 mg.
[0011] The specific needle solution composition is as follows: 40 mg doxorubicin hydrochloride, 4.3 mg ganciclovir, 300 mg HA and 1 mL ultrapure water; when preparing the backing layer, the prepared backing layer material solution is a HA aqueous solution, wherein the mass ratio of HA to water is 1:10.
[0012] The molecular weight of HA at the needle tip in the present invention is 10 kDa, and the molecular weight of HA at the base is 200-400 kDa.
[0013] The ganciclovir soluble microneedle patch of the present invention has a cone-shaped needle body, a height of the needle body of 800 μm, and a bottom diameter of the needle body of 300 μm.
[0014] The thickness of the backing layer of the ganciclovir soluble microneedle patch of the present invention is 300-600 μm.
[0015] The present invention also provides a method for preparing a ganciclovir soluble microneedle patch, comprising the following steps: 1) Add the needle material solution required for preparing the needle body into the PDMS microneedle mold, centrifuge to remove bubbles, and dry in a drying oven for 40 o C for two hours and repeat twice to obtain the needle tip.
[0016] 2) pouring the backing layer material solution required for preparing the backing layer, centrifuging again to remove bubbles, drying at room temperature overnight, and demolding to obtain the combined drug soluble microneedle patch.
[0017] The present invention adopts the PDMS mold method to prepare the combined drug soluble microneedle patch, and uses its formability, solubility and puncture performance as the evaluation index, and single factors are used to investigate the solvent, matrix, centrifugation time and drying method for preparing the soluble microneedle; the prepared microneedle is evaluated, including morphology, mechanical properties, solubility, and finally the Franz diffusion cell is used to investigate the in vitro transdermal performance of ganciclovir. The experiment determined that the needle body of the combined drug soluble microneedle is conical, with a height of 800 μm, a bottom diameter of 300 μm, a uniform morphology, and the drug is mainly concentrated at the needle tip, which can ensure that the drug can be completely delivered to the body.
[0018] The transdermal release performance of the ganciclovir-doxorubicin combination drug soluble microneedle patch is determined by performing an in vitro transdermal experiment using a RhB@GCV / DOX microneedle Franz diffusion cell, collecting samples containing rhodamine, and testing the rhodamine fluorescence intensity to obtain the total release amount.
[0019] The beneficial effects of the present invention are as follows: the soluble microneedles for combined use of ganciclovir and doxorubicin prepared by the present invention have good mechanical strength and sufficient mechanical properties to penetrate the skin, and the needle tip can be quickly dissolved, thereby achieving transdermal delivery of ganciclovir and solving the problem of targeted treatment of ganciclovir. The combined drug soluble microneedles can achieve the effect of treating human herpes virus type 8. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 Characterization of microneedle morphology: A1 and A3: morphology and SEM images of ganciclovir-doxorubicin combined drug microneedle characterized by optical microscope; A2: morphology of rhodamine B microneedle characterized by optical microscope; Figure 2 This is a mechanical test diagram of the combined drug microneedle; Figure 3 This is a combined drug microneedle in vitro skin penetration test: A1-A2: overhead and side-section images of different sections of the mouse skin after the Rhodamine B soluble microneedle test; A3: overhead image after the microneedle was attached to the mouse skin; Figure 4 This is the measurement diagram of microneedle drug release in in vitro transdermal experiment; Figure 5 This is a graph showing the experimental data of drug toxicity to in vitro cells; Figure 6 This is a graph showing the changes in mouse body weight and tumor volume during treatment; Figure 7 HE staining to observe the pathological changes of the heart, liver, spleen, kidney and tumor of mice after the microneedle patch treatment; DETAILED DESCRIPTION
[0021] The present invention is further described below in conjunction with specific embodiments, but the present invention is not limited to the following embodiments.
[0022] The experimental methods in the following examples are all conventional methods.
[0023] Example 1 Preparation of Ganciclovir Doxorubicin Microneedles: Matrix material of Ganciclovir-loaded microneedles: Needle body material: GCV / DOX mixed solution: 40 mg / mL DOX, 4.3 mg / mL GCV, 300 mg / mL HA. The specific composition is as follows: 40 mg / mL DOX, 4.3 mg / mL GCV +1 mL H2O+300 mg HA; Backing layer material: 10% HA solution (HA: water = 1:10, w / w) The preparation method is as follows: placing the needle body material solution in a PDMS microneedle mold, centrifuging to remove bubbles and drying, repeating twice; pouring a backing layer solution in the PDMS microneedle mold, centrifuging to remove bubbles and drying again, and demolding to obtain a ganciclovir-doxorubicin combination drug microneedle.
[0024] Figure 1 A1 is the morphology of the combined drug soluble microneedles prepared in Example 1 characterized under an optical microscope; A3 is the SEM image of the combined drug soluble microneedles.
[0025] 5% rhodamine B was added to the needle tip material in the above embodiment to prepare RhB@GCV / DOX microneedles, and the fluorescence emitted by rhodamine B was used to characterize the morphology of the microneedles. Figure 1 A2 in the middle is the morphology of the microneedles loaded with rhodamine B.
[0026] As can be seen from the figure, the microneedle is conical, with a height of 800 μm, a bottom diameter of 300 μm, and a uniform morphology.
[0027] Example 2 Force-displacement curve of microneedle tested by dynamometer: The specific test method is: the microneedle prepared in Example 1 is placed on a pressure tester for measurement, and the test results are as follows: Figure 2As shown in the figure, a single needle can withstand a force of about 0.07 N and can penetrate the skin. Therefore, from the force-displacement curve, it can be seen that the ganciclovir-doxorubicin combination microneedle has sufficient mechanical properties to ensure that it can penetrate the skin without breaking.
[0028] Example 3 Characterization of mechanical properties of microneedles - In vitro skin penetration test: The microneedles prepared in Example 1 above were subjected to an in vitro skin penetration test. The specific test method is: take fresh mouse ex vivo skin, remove the surface hair and subcutaneous fat, quickly press the microneedle on the skin for 5 minutes and then remove it, and observe the pinholes in the skin under an optical microscope. Repeat the above operation, use a rhodamine B-loaded patch to stick on the mouse ex vivo skin, place the skin in neutral formalin for fixation, stain, and slice, and use a fluorescent confocal microscope to observe the fluorescent images of microneedles at different layers of the mouse skin and the cross-sectional images after staining. Figure 3 From A1, we can see that the microneedle has sufficient mechanical properties to penetrate the mouse skin, and there is fluorescence of the dissolved microneedle at 120 μm. From A2, we can see that the microneedle can penetrate 450 μm below the skin of the mouse's back, that is, the microneedle can pierce the epidermis and dermis and release the drug.
[0029] All mechanical property tests are performed to demonstrate that the prepared microneedles have sufficient mechanical properties to penetrate the skin for drug delivery.
[0030] Example 4 Microneedle release test: The RhB@GCV / DOX microneedle release prepared in the above example was tested using a Franz diffusion cell. The specific test method is as follows: The simulated skin was placed between the supply chamber and the receiving chamber of the diffusion cell, 20 mL of PBS (PH=7.4) was added to the receiving chamber, heated to 37°C, and the magnetic stirring speed was adjusted to 500 rpm. The Rhodamine B-loaded microneedle patch was placed on the skin in the supply chamber, and 600 μL of the receiving solution was taken out from the receiving chamber at 0 h, 1 h, 2 h, 4 h, 6 h, 12 h, 18 h, 24 h, 36 h, 48 h, and 72 h, and the fluorescence intensity was measured by a fluorescence detector.
[0031] The test results are as follows Figure 4 shown. Figure 4 The release curve shows that the soluble microneedles have been continuously releasing drugs and can reach a release effect of 70% in 24 hours, which can meet the drug administration needs. After that, the release rate was measured until 72 hours, and it was still 70%, indicating that the drug was completely released in 24 hours.
[0032] Example 5 In vitro cytotoxicity experiment: The model cells used in this experiment are KMM cells positive for human herpesvirus type 8. KMM cells are rat embryonic metanephric mesenchymal precursor cells latently infected with human herpesvirus type 8 (KSHV-transformed rat primary mesenchymal precursor cells). In this experiment, DMSO was used as the control group, and the MTT method was used to detect the cytotoxicity of KMM cells. KMM cells were placed in a 96-well plate at a density of 5000 cells / well and incubated overnight in DMEM medium containing 10% FBS, 37°C, and 5% CO2. After the cells adhered to the wall, GCV, DOX+GCV, and ganciclovir doxorubicin microneedles were added to the culture medium. After continuing to culture for 24 hours, 10 μL of MTT solution was added to each well, and 100 μL of triple solution was added to each well after 4 hours. After overnight, the absorbance value at 570 nm was measured using an ELISA reader. Calculate the inhibition rate of the drug on the cells, the calculation formula: inhibition rate (%) = (absorbance value of the control group - absorbance value of the drug group) / (absorbance value of the control group - absorbance value of the blank group) × 100%. Figure 5 It can be seen that GCV alone has basically no toxicity to cells, and GCV shows good toxicity after combining with DOX. The microneedle group has the same effect as the combined medication group, indicating that the microneedle can release drugs to damage cells.
[0033] Implementation Figure 6 Experiment on the in vivo therapeutic effect of soluble microneedles: 20 female Balb / c mice of the same age were prepared. Each mouse was injected with KMM cells to construct a model. After the model was established, the mice were randomly divided into 4 groups, with five mice in each group, namely the control group, blank microneedle group, drug injection group and drug microneedle group. The control group did not receive any treatment. The injection group and the microneedle group were treated once every four days. The drug injection group was injected peritumorally, and each mouse was injected with 100 mL of a mixture of doxorubicin and ganciclovir. The microneedle treatment group was anesthetized with isoflurane for pets and then the microneedles were attached to the tumor for treatment. The weight and tumor volume of the mice were recorded every four days. Figure 6 It can be seen that the weight of mice increased during the treatment, indicating that the treatment process was minimally toxic to the mice; compared with the control group, the tumor volume of the treatment group was significantly reduced, indicating that microneedling has a significant therapeutic effect on herpes sarcoma.
[0034] Example 7 H&E staining: After the mouse experiment, the mouse tumors, heart, liver, spleen, lungs, and kidneys were taken and fixed for H&E staining analysis. Figure 7It can be seen that compared with the control group and the blank microneedle group, the H&E staining showed that the nerve fibers in the heart, liver, spleen, lung and kidney experimental group were evenly distributed, with no obvious changes, indicating that the treatment process had no systemic toxicity to the mice. In the control group and the blank control group, the tumor cells grew diffusely, with dense and disordered arrangement, no tissue structure, and the cancer cells had abundant cytoplasm, overlapping nuclei, and obvious atypia. The cytoplasm and nuclei of the experimental group were lightly stained, and it can be seen that there was a significant therapeutic effect.
[0035] In summary, the ganciclovir and doxorubicin combined drug soluble microneedle patch prepared by the present invention can have a certain effect on the treatment of human herpes simplex virus type 8.
Claims
1. A microneedle patch, characterized in that The microneedle patch comprises a base and needle bodies loaded with drugs, wherein the drug needle bodies are arranged on the base in an array form, and the microneedles forming the drug needle bodies are soluble in water and can release drug molecules.
2. The soluble microneedle composition of ganciclovir-adriamycin combination drug according to claim 1, characterized in that: The needle material includes the following components: 40 mg / mL DOX, 4.3 mg / mL GCV, and 100 mg / mL polymer skeleton.
3. The combined drug soluble microneedle patch according to claim 2, characterized in that: the needle body matrix material and the backing layer material are both HA. The molecular weight of the needle body matrix material HA is 10 kDa, and the molecular weight of the backing layer material HA is 200-400 kDa.
4. The ganciclovir soluble microneedle according to claim 1, characterized in that: The mass ratio of the needle body material to the base material is 3:(40-100).
5. The soluble microneedle of ganciclovir-adriamycin combination drug according to claim 1 or 2, characterized in that: The combined drug soluble microneedle has a 15×15 array of needle bodies, a single needle body is conical, the height of the needle body is 800 μm, and the bottom diameter of the needle body is 300 μm; The thickness of the backing layer is 300-600 μm.
6. The method for preparing the combined drug soluble microneedle composition according to any one of claims 1 to 5, characterized in that: The following steps are involved: S1: preparing needle body material solution and base material solution; S2: Add the needle material solution into the microneedle negative mold, centrifuge, remove the excess solution, 40 o C drying for 2 h, repeat twice to obtain the needle tip; S3: adding the substrate material solution, centrifuging for 6 minutes, and then drying at room temperature overnight and demolding to obtain the ganciclovir soluble microneedle composition.
7. The method for preparing the soluble microneedle of ganciclovir-adriamycin combination drug according to claim 6, characterized in that: The centrifugation step specifically includes: centrifuging for 6 min at a centrifugal speed of 3000-3910 rpm.
8. The method for preparing the combined drug soluble microneedle according to claim 6, characterized in that: The step of preparing the needle body material solution is specifically: mixing the drugs doxorubicin hydrochloride and ganciclovir with a solvent, and then mixing with hyaluronic acid to prepare the needle body material solution.
9. The method for preparing the ganciclovir soluble microneedle composition according to claim 6, characterized in that: The step of preparing the substrate material solution is specifically: mixing the substrate material with a solvent to prepare a 30% (w / w) substrate solution.
10. Use of the microneedle patch according to any one of claims 1 to 6 for preparing a targeted diagnosis and treatment patch for human herpes virus type 8.
